Consistent with the TCGA analysis, PBRM1 mutations were most common in ccRCC patients (46.6%), followed by non-melanoma skin cancer (9%) and melanoma (8%), while ARID2 was most common in melanoma (13%), followed by non-melanoma skin cancer and colorectal cancer (11%) (Supplementary Fig. 2). Here, ARID2 is linked to colorectal cancer.